Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Japan Pharmacist Group Renews Opposition to Off-Year Re-Pricing in FY2021
May 22, 2020
- Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
May 21, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- Don’t Give Hasty COVID-19 Nod for Existing Drugs, Follow Int’l Rules for Avigan Approval: JMA
May 21, 2020
- Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
May 18, 2020
- FPMAJ to Continue COVID-19 Impact Survey on Drug Supplies
May 18, 2020
- Japan Pharmacist Group Opposes Off-Year Re-Pricing in FY2021
May 1, 2020
- PhRMA, EFPIA Issue Joint Statement on Air Transporting Critical Medicines amid COVID-19 Outbreak
April 30, 2020
- JMA Calls for Early Avigan Use in High-Risk Patients Hospitalized with COVID-19
April 30, 2020
- IFPW Postpones Tokyo General Meeting to October 2021
April 27, 2020
- SMA Patient Group Presses MHLW to Hasten Zolgensma Listing
April 17, 2020
- FPMAJ Ups Ante for Drug Supply Coordination amid COVID-19 Crisis
April 14, 2020
- EFPIA Japan Says No Drug Shortages for Now, but Warns of Fluid Situation
April 8, 2020
- JPMA to Vet Impact of Drug Pricing Reform, Make Proposals for R&D Tax Break System: FY2020 Project Plan
April 8, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
- Keidanren Calls for Support in Drug, Vaccine Development: Emergency Proposal
March 31, 2020
- Japan Pharma Industry Presses for 100 Billion Yen Emergency Package over Coronavirus, Stable Supplies
March 31, 2020
- FPMAJ Launches Survey to Gauge COVID-19 Impact on Drug Supplies
March 27, 2020
- Generic Use Rate at 77.1% in October-December 2019: JGA
March 27, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…